Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones

insidermonkey.com · 2026-09-27

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is building a business model that differs from that of many drug developers.

TickrTrends take: Ligand's funding arrangement with AvenCell, where most capital is contingent on achieving milestones, suggests the company is managing cash deployment cautiously rather than committing large upfront investments. This milestone-based structure reduces near-term cash burn but also introduces execution risk that could affect the company's ability to realize the deal's full financial benefit. Given TickrTrends' current assessment that LGND is overvalued, investors focused on valuation metrics should monitor whether Ligand can meet these milestones efficiently and whether the deal ultimately delivers sufficient returns to justify current pricing in the Healthcare sector.

Read the full story at insidermonkey.com →